These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 31556749)

  • 1. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.
    Wang Y; De Clercq E; Li G
    Expert Opin Drug Metab Toxicol; 2019 Oct; 15(10):813-829. PubMed ID: 31556749
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging reverse transcriptase inhibitors for HIV-1 infection.
    Rai MA; Pannek S; Fichtenbaum CJ
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):149-157. PubMed ID: 29737220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.
    Jayaweera D; Dilanchian P
    Expert Opin Pharmacother; 2012 Dec; 13(18):2601-12. PubMed ID: 23176566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Balzarini J
    Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of the interaction when switching non-nucleoside reverse transcriptase inhibitors in patients infected with HIV.
    Dailly E; Allavena C; Deslandes G; Bouquie R; Jolliet P; Raffi F
    Curr Clin Pharmacol; 2014; 9(4):399-403. PubMed ID: 24218996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Penazzato M; Giaquinto C
    Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etravirine for the treatment of HIV/AIDS.
    Schrijvers R
    Expert Opin Pharmacother; 2013 Jun; 14(8):1087-96. PubMed ID: 23560740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine.
    Boyle A; Moss CE; Marzolini C; Khoo S
    Clin Pharmacokinet; 2019 Dec; 58(12):1553-1565. PubMed ID: 31388941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of etravirine in combination antiretroviral therapy].
    Domingo P
    Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():46-51. PubMed ID: 20116628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
    Zhang Z; Hamatake R; Hong Z
    Antivir Chem Chemother; 2004 May; 15(3):121-34. PubMed ID: 15266894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
    Namasivayam V; Vanangamudi M; Kramer VG; Kurup S; Zhan P; Liu X; Kongsted J; Byrareddy SN
    J Med Chem; 2019 May; 62(10):4851-4883. PubMed ID: 30516990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009).
    de Béthune MP
    Antiviral Res; 2010 Jan; 85(1):75-90. PubMed ID: 19781578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
    De Clercq E
    Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
    Moyle G
    Drugs; 2001; 61(1):19-26. PubMed ID: 11217868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    Sterrantino G; Borghi V; Callegaro AP; Bruzzone B; Saladini F; Maggiolo F; Maffongelli G; Andreoni M; De Gennaro M; Gianotti N; Bagnarelli P; Vergori A; Antinori A; Zazzi M; Zaccarelli M;
    Int J Antimicrob Agents; 2019 Apr; 53(4):515-519. PubMed ID: 30769200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational Design of Doravirine: From Bench to Patients.
    Hwang C; Lai MT; Hazuda D
    ACS Infect Dis; 2020 Jan; 6(1):64-73. PubMed ID: 31621289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical uses of non-nucleoside reverse transcriptase inhibitors.
    Harris M; Montaner JS
    Rev Med Virol; 2000; 10(4):217-29. PubMed ID: 10891870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.
    Usach I; Melis V; Peris JE
    J Int AIDS Soc; 2013 Sep; 16(1):1-14. PubMed ID: 24008177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.